Skip to main content
. 2020 Nov 10;10:569887. doi: 10.3389/fonc.2020.569887

Figure 2.

Figure 2

Survival analyses of PINK1 expression in pan-cancers (based on PrognoScan). (A) OS (n = 163) in blood cancer cohort GSE12417-GPL96. (B) OS (n = 77) in brain cancer cohort GSE4217-GPL96. (C) RFS (n = 77) in breast cancer cohort GSE9195. (D) DMFS (n = 286) in breast cancer cohort GSE2034. (E) DFS (n = 226) in colorectal cancer cohort GSE14333. (F) OS (n = 82) in lung cancer cohort jacob-00182-CANDF. (G) OS (n = 133) in ovarian cancer cohort DUKE-OC. (H) OS (n = 81) in ovarian cancer cohort GSE8841. (I) DRFS (n = 140) in soft tissue cancer cohort GSE30929. OS, overall survival; DMFS, distant metastasis free survival; RFS, relapse free survival; DFS, disease free survival; DRFS, distant recurrence free survival.